Aligos Therapeutics

ALGS

Market cap $65.1M

Overview Fund Activity

9.37 USD

-0.83

8.14%

At close Updated Sep 15, 4:00 PM EDT

1 day

-8.14%

5 days

-13.96%

1 month

21.69%

3 months

16.4%

6 months

-19.71%

Year to date

-76.47%

1 year

-34.11%

5 years

-97.48%

10 years

-97.48%

About: Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.

Employees: 70

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

29% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 7

25% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 8

6% more funds holding

Funds holding: 35 [Q1] → 37 (+2) [Q2]

11.13% less ownership

Funds ownership: 62.06% [Q1] → 50.93% (-11.13%) [Q2]

28% less capital invested

Capital invested by funds: $27.1M [Q1] → $19.5M (-$7.53M) [Q2]

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target

$50

434% upside

Avg. target

$50

434% upside

High target

$50

434% upside

1 analyst rating

1 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co.

Patrick R. Trucchio

$50

Buy

Reiterated

12 Sep 2025

See Analyst Rankings

Financial journalist opinion

Based on 5 articles about ALGS published over the past 30 days

Zacks Investment Research

Does Aligos Therapeutics (ALGS) Have the Potential to Rally 737.74% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 737.7% in Aligos Therapeutics (ALGS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Does Aligos Therapeutics (ALGS) Have the Potential to Rally 737.74% as Wall Street Analysts Expect?

Aligos Therapeutics Announces Six Preclinical Presentations at the 2025 International HBV Meeting

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced six presentations, including three oral presentations, at the 2025 International HBV Meeting, being held September 8 – 12, 2025 in Berlin, Germany.

Aligos Therapeutics Announces Six Preclinical Presentations at the 2025 International HBV Meeting

Aligos Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that members of management will present at the H.C. Wainwright 27th Annual Global Investment Conference being held September 8-10, 2025.

Aligos Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Ramón Polo as Senior Vice President, Head of Global Regulatory Affairs

SOUTH SAN FRANCISCO, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Ramón Polo, PharmD, PhD, MBA as Senior Vice President, Head of Global Regulatory Affairs, effective immediately.

Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Ramón Polo as Senior Vice President, Head of Global Regulatory Affairs

Zacks Investment Research

Wall Street Analysts Predict a 983.24% Upside in Aligos Therapeutics (ALGS): Here's What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 983.2% in Aligos Therapeutics (ALGS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Predict a 983.24% Upside in Aligos Therapeutics (ALGS): Here's What You Should Know

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Aug. 15, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Compensation Committee of the Company's Board of Directors granted non-qualified stock options to purchase an aggregate of 42,300 shares of the Company's stock (the “Inducement Grant”) to newly hired employees on August 12, 2025 (the “Grant Date”), in connection with the commencement of employment.

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aligos Therapeutics Announces First Subject Dosed in the Phase 2 B-SUPREME Study of ALG-000184 in Subjects with Chronic HBV Infection

SOUTH SAN FRANCISCO, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that dosing in the Phase 2 B-SUPREME study of its investigational compound ALG-000184 has been initiated in subjects with chronic hepatitis B virus (HBV) infection.

Aligos Therapeutics Announces First Subject Dosed in the Phase 2 B-SUPREME Study of ALG-000184 in Subjects with Chronic HBV Infection

Zacks Investment Research

Aligos Therapeutics, Inc. (ALGS) Reports Q2 Loss, Misses Revenue Estimates

Aligos Therapeutics, Inc. (ALGS) came out with a quarterly loss of $1.53 per share versus the Zacks Consensus Estimate of a loss of $2.35. This compares to earnings of $0.75 per share a year ago.

Aligos Therapeutics, Inc. (ALGS) Reports Q2 Loss, Misses Revenue Estimates

Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results

SOUTH SAN FRANCISCO, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today reported recent business progress and financial results for the second quarter 2025.

Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results

Aligos Therapeutics to Announce 2nd Quarter 2025 Financial Results on August 6, 2025

SOUTH SAN FRANCISCO, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that it will report the Company's second quarter 2025 financial results on Wednesday, August 6, 2025, after the close of the U.S. financial markets.

Aligos Therapeutics to Announce 2nd Quarter 2025 Financial Results on August 6, 2025

See News Rankings

Charts implemented using Lightweight Charts™